Clinical Trials Browser

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT01750073 2025-11-18

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Phase 2 Active not recruiting

92 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05445908 2025-11-17

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Phase 2 Active not recruiting

175 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05949021 2025-11-14

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

Phase 2 Active not recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05455658 2025-10-24

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 2 Active not recruiting

33 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04443348 2025-10-14

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Phase 2 Active not recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04837209 2025-10-01

NADiR

Phase 2 Active not recruiting

32 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05491226 2025-08-27

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Phase 2 Active not recruiting

35 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04083963 2025-07-10

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

Phase 2 Active not recruiting

13 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02755272 2025-07-04

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

87 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Phase 2 Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

Phase 2 Active not recruiting

29 enrolled 11 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04445844 2025-04-04

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Phase 2 Active not recruiting

25 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02644369 2025-03-26

INSPIRE

Phase 2 Active not recruiting

100 enrolled

BreastDermatologicGynecologic

Carcinoma, Ovarian Epithelial, Melanoma, Triple Negative Breast Neoplasms

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02547987 2025-03-12

CADENCE

Phase 2 Active not recruiting

25 enrolled 9 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05498896 2025-03-10

BARBICAN

Phase 2 Active not recruiting

146 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04807192 2025-02-27

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

Phase 2 Active not recruiting

40 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04418154 2024-05-21

NeoTENNIS

Phase 2 Active not recruiting

70 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05145907 2024-04-15

Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Phase 2 Active not recruiting

133 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Active not recruiting

120 enrolled 12 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03756298 2023-11-09

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Phase 2 Active not recruiting

284 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02315196 2023-03-29

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Phase 2 Active not recruiting

62 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03012100 2023-01-13

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Phase 2 Active not recruiting

280 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

InCITe

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

TELESCOPE

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

SKYLINE

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

ToPCourT

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

NADiR

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

INSPIRE

ACROPOLI

CADENCE

BARBICAN

CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)

NeoTENNIS

Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

NeoPACT

Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer